SPY322.50-1.00 -0.31%
DIA267.03-1.08 -0.40%
IXIC10,662.74-9.53 -0.09%

Akebia Therapeutics Announces Commercial Launch Of VAFSEO Oral Treatment For Anemia Due To Chronic Kidney Disease, In Japan

CAMBRIDGE, Mass., Aug. 26, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today

 · 

CAMBRIDGE, Mass., Aug. 26, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is now commercially available in Japan as a treatment for anemia due to chronic kidney disease (CKD) under the trade name VAFSEO™. VAFSEO has been included in the Japan National Health Insurance drug price listing and was granted regulatory approval as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour and Welfare in Japan in June 2020. The starting dose for VAFSEO is indicated at 300 mg with a maximum dose indicated at 600 mg.